By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Pfizer Inc. et al v. Teva Pharmaceuticals USA Inc.
1:07-cv-00360; filed June 7, 2007 in the District Court of Delaware

Infringement of U.S. Patent No. 5,273,995 ("[R-(R*R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof," issued December 28, 1993) based on Teva's filing of an ANDA to manufacture a generic version of Pfizer's Lipitor® (atorvastatin calcium, used to treat high cholesterol and heart disease).  View the complaint here.

Purdue Pharma L.P. et al v. KV Pharmaceutical Company
1:07-cv-04810; filed June 6, 2007 in the Southern District of New York

Infringement of U.S. Patent Nos. 5,508,042 ("Controlled Release Oxycodone Compositions," issued April 16, 1996), 5,549,912 (same title, issued August 27, 1996), and 5,656,295 (same title, issued August 12, 1997) following a paragraph IV certification as part of KV's and Actavis' filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.